Diabetic neuropathies are a disabling condition and the most common form has been estimated to occur in at least 20% of people with type 1 diabetes after 20 years of disease duration, and 10-15% of newly diagnosed patients with type 2 diabetes, increasing to 50% after. There are several treatment options for those who present with symptoms.
Further to a recent recall of RestoraLAX 45+10, Health Canada is advising Canadians that Bayer Inc. is expanding its voluntary recall to include specific lots of RestoraLAX 30+7 Bonus Packs due to a potential choking hazard.